clinical_trial

Donanemab in Early Symptomatic Alzheimer's (TRAILBLAZER-ALZ 2)

created 4/30/2026, 2:41:24 PM

History Diff Edit
completed phase_3 NCT04437511
Intervention
Donanemab (anti-N3pG amyloid)
Sponsor
Eli Lilly
Registered
Apr 30, 2026

Voting as anonymous. Sign in to attribute your signals.

tokens

Replication

No replications yet

Discussion

Posting anonymously. Sign in for attribution.

No comments yet — be the first.